Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Pharmacokinetics and pharmacodynamics of norfluoxetine in rats: Increasing extracellular serotonin level in the frontal cortex.

Qu Y, Aluisio L, Lord B, Boggs J, Hoey K, Mazur C, Lovenberg T.

Pharmacol Biochem Behav. 2009 May;92(3):469-73. doi: 10.1016/j.pbb.2009.01.023. Epub 2009 Feb 5.

PMID:
19463261
2.

Role of 5-HT1A receptors in the effects of acute chronic fluoxetine on extracellular serotonin in the frontal cortex.

Invernizzi R, Bramante M, Samanin R.

Pharmacol Biochem Behav. 1996 May;54(1):143-7.

PMID:
8728551
4.

Effects of fluoxetine and norfluoxetine on 5-hydroxytryptamine metabolism in blood platelets and brain after administration to rats.

Bourdeaux R, Desor D, Lehr PR, Younos C, Capolaghi B.

J Pharm Pharmacol. 1998 Dec;50(12):1387-92.

PMID:
10052854
5.

Effects of acute fluoxetine on extracellular serotonin levels in the raphe: an in vivo microdialysis study.

Malagié I, Trillat AC, Jacquot C, Gardier AM.

Eur J Pharmacol. 1995 Nov 14;286(2):213-7.

PMID:
8605960
6.
7.

Regional differences in the effect of the combined treatment of WAY 100635 and fluoxetine: an in vivo microdialysis study.

Malagié I, Trillat AC, Douvier E, Anmella MC, Dessalles MC, Jacquot C, Gardier AM.

Naunyn Schmiedebergs Arch Pharmacol. 1996 Dec;354(6):785-90.

PMID:
8971740
8.

Fluoxetine bioequivalence study: quantification of fluoxetine and norfluoxetine by liquid chromatography coupled to mass spectrometry.

Moraes MO, Lerner FE, Corso G, Bezerra FA, Moraes ME, De Nucci G.

J Clin Pharmacol. 1999 Oct;39(10):1053-61.

PMID:
10516940
9.

A validated enantioselective assay for the simultaneous quantitation of (R)-, (S)-fluoxetine and (R)-, (S)-norfluoxetine in ovine plasma using liquid chromatography with tandem mass spectrometry (LC/MS/MS).

Chow TW, Szeitz A, Rurak DW, Riggs KW.

J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Feb 15;879(5-6):349-58. doi: 10.1016/j.jchromb.2010.12.020. Epub 2010 Dec 29.

PMID:
21242112
10.
11.

Norfluoxetine enantiomers as inhibitors of serotonin uptake in rat brain.

Wong DT, Bymaster FP, Reid LR, Mayle DA, Krushinski JH, Robertson DW.

Neuropsychopharmacology. 1993 Jun;8(4):337-44.

12.
13.

Effects of chronic fluoxetine treatment in the presence and absence of (+/-)pindolol: a microdialysis study.

Dawson LA, Nguyen HQ, Smith DI, Schechter LE.

Br J Pharmacol. 2000 Jun;130(4):797-804.

14.
15.

Anorectic activity of fluoxetine and norfluoxetine in rats: relationship between brain concentrations and in-vitro potencies on monoaminergic mechanisms.

Caccia S, Bizzi A, Coltro G, Fracasso C, Frittoli E, Mennini T, Garattini S.

J Pharm Pharmacol. 1992 Mar;44(3):250-4.

PMID:
1354734
16.

Pharmacokinetics of fluoxetine in rhesus macaques following multiple routes of administration.

Sawyer EK, Howell LL.

Pharmacology. 2011;88(1-2):44-9. doi: 10.1159/000329417. Epub 2011 Jul 14.

17.

Effects of fluoxetine on convulsions and on brain serotonin as detected by microdialysis in genetically epilepsy-prone rats.

Dailey JW, Yan QS, Mishra PK, Burger RL, Jobe PC.

J Pharmacol Exp Ther. 1992 Feb;260(2):533-40.

PMID:
1738103
18.

Effect of fluoxetine on extracellular 5-hydroxytryptamine in rat brain. Role of 5-HT autoreceptors.

Hervás I, Artigas F.

Eur J Pharmacol. 1998 Sep 25;358(1):9-18.

PMID:
9809863
19.

Comparison of norfluoxetine enantiomers as serotonin uptake inhibitors in vivo.

Fuller RW, Snoddy HD, Krushinski JH, Robertson DW.

Neuropharmacology. 1992 Oct;31(10):997-1000.

PMID:
1279447
20.

Unsuspected poor metabolizer phenotypes of fluoxetine in bioavailability/bioequivalence studies from an indian population perspective. Retrospective pharmacokinetic data evaluation.

Kandasamy M, Tripathy K, Ravi S, Kamath N, Pai B, Srinivas NR, Kristjansson F, Thangam S.

Arzneimittelforschung. 2010;60(1):12-21. doi: 10.1055/s-0031-1296243.

PMID:
20184222

Supplemental Content

Support Center